Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

Interview

Vedolizumab Tolerable for Prevention of GVHD in Patients Undergoing Allo-HSCT

02/01/2021

Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.

Study findings showed that...

02/01/2021

Oncology

Interview

New Therapeutic Target for GVHD Could Make Bone Marrow Transplant Safer

01/01/2021

Xue-Zhong Yu, MD, MS, MBA, discusses Sirtuin-1 as a possible therapeutic target for the control of GVHD.

Xue-Zhong Yu, MD, MS, MBA,...

01/01/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

Recent News

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine ;

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology